Myogaster-E inj. opl. i.m. flac. Ubelgiji - Kiholanzi - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

myogaster-e inj. opl. i.m. flac.

v.m.d. - watervrij natriumseleniet 1.315 mg/ml - eq. selenium 0.6 mg/ml; dl-alfa-tocoferylacetaat 100 mg/ml - oplossing voor injectie - watervrij natriumseleniet 1.315 mg/ml; dl-alfa-tocoferylacetaat 100 mg/ml - vitamins with minerals - rund; schaap; varken

Dufavit E+SEL W.O. Uholanzi - Kiholanzi - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

dufavit e+sel w.o.

dutch farm international b.v. - dinatriumseleniet 0-water; tocoferol, dl-alfa acetaat - poeder voor oraal gebruik - dinatriumseleniet 0-water 0,3 mg/g; tocoferol, dl-alfa acetaat 40 mg/g, - vitamins with minerals - biggen; kalveren; lammeren; slachtpluimvee; varkens

Vitamine E + Selenium 17 mg/ml - 1,67 mg/ml inj. emuls. i.m. flac. Ubelgiji - Kiholanzi - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vitamine e + selenium 17 mg/ml - 1,67 mg/ml inj. emuls. i.m. flac.

v.m.d. - natriumselenietpentahydraat 1.67 mg/ml; d-alfa-tocoferylacetaat 17 mg/ml - emulsie voor injectie - 17 mg/ml - 1,67 mg/ml - natriumselenietpentahydraat 1.67 mg/ml; dl-alfa-tocoferylacetaat 17 mg/ml - selenium, combinations - rund; schaap; varken

Fingolimod Mylan Umoja wa Ulaya - Kiholanzi - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod hydrochloride - multiple sclerose, relapsing-remitting - immunosuppressiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 en 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.